It has been a bumpy road but Novartis has made a major leap in advancing an intrathecal version of its spinal muscular atrophy (SMA) gene therapy Zolgensma which would significantly expand the number of people who would be eligible to receive the transformational drug.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?